About US
Contact us
Position：Home > Phexcom News >
-
Small flu vax players poised to win 'sizable' share of market, firm predictsAs new flu vaccine technology emerges in the coming years, smaller players will have a shot at stealing market share from the world leaders who have for years had a hold on the market. That’s the2016/12/2
-
Merck's Keytruda snags second FDA 'priority' tag this week, this time in Hodgkin'sMerck’s Keytruda has nabbed its second FDA priority review tag of the week—and it’s one that’ll help it gain ground on archrival Opdivo from Bristol-Myers Squibb. Thursday, the New Jersey drugmakeran2016/12/2
-
FDA: Infections prompt recall of all Specialty Compounding's sterile medsMore suspect drugs from a compounding pharmacy: The FDA says Specialty Compounding is yanking all of its sterile products after 15 patients at two Texas hospitals contracted bacterial bloodstream infe2016/12/1
-
Food regulators seize adulterated milk products for food safety violationsThe U.S. Food and Drug Administration announced today that the U.S. Marshals Service seized more than 4 million pounds of product produced by Valley Milk Products LLC (Valley Milk) of Strasburg, Virgi2016/11/30
-
Analysts to Wall Street: Don't celebrate yet. The drug-pricing brouhaha is far from overWhen presidential candidate Hillary Clinton blasted Martin Shkreli on Twitter for hiking the price of an old drug called Daraprim by 5,000% in September 2015, biotech stocks plummeted. Clinton tweeted2016/11/29
-
Astellas scouts pipeline buys for post-Xtandi futureHaving built a fortune on a lucrative Xtandi partnering deal, Astellas is scouting for a new round of assets to deliver growth in its next chapter. The Japanese drugmaker is joining the likes of large2016/11/29
-
The Fifth PhExFEST & International Pharmaceutical Formulation Technology Development ForumThe Fifth PhExFEST & International Pharmaceutical Formulation Technology Development Forum The 5th PhExFEST& 2016 International Pharmaceutical Formulation Tachnology Development Forum held in2016/6/2
-
Novartis would sell its Roche stake without a premium, CEO saysNovartis ($NVS) has been reluctant to sell its big stake in neighboring Swiss pharma Roche ($RHHBY) unless it got a premium. Now, the company is changing its tune. Novartis “would potentially make a2016/5/27
-
GSK hopes to keep the Breo train rolling with new real-world COPD dataGlaxoSmithKline’s blockbuster wannabe Breo is finally picking up steam--and the British drugmaker has some new data it hopes can keep that trend going strong. On Tuesday, it rolled out results from a2016/5/27
-
The Chinese and European Pharmacopoeias – The new editionsThis one-day Stakeholder workshop, co-organised by the Chinese Pharmacopoeia Commission, the China Pharmaceutical Association of Plant Engineering (CPAPE) and the EDQM will explore the current trends2016/2/19